Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Liabilities (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Total Liabilities data on record, last reported at $3.1 billion in Q4 2025.

  • For Q4 2025, Total Liabilities rose 10.74% year-over-year to $3.1 billion; the TTM value through Dec 2025 reached $3.1 billion, up 10.74%, while the annual FY2025 figure was $3.1 billion, 10.74% up from the prior year.
  • Total Liabilities reached $3.1 billion in Q4 2025 per PTCT's latest filing, up from $2.8 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $3.1 billion in Q4 2025 and bottomed at $1.8 billion in Q3 2022.
  • Average Total Liabilities over 5 years is $2.3 billion, with a median of $2.1 billion recorded in 2022.
  • Peak YoY movement for Total Liabilities: surged 105.95% in 2021, then decreased 5.21% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $1.9 billion in 2021, then rose by 5.99% to $2.1 billion in 2022, then soared by 32.23% to $2.7 billion in 2023, then grew by 3.27% to $2.8 billion in 2024, then increased by 10.74% to $3.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $3.1 billion in Q4 2025, $2.8 billion in Q3 2025, and $2.8 billion in Q2 2025.